ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Sodium Hydroxide → (8S)-9-[2-(3-chloro-phenyl)ethyl]-2-(morpholin-4-yl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one

HRID 80631
印刷

反応式

HRID 80631 の反応式
[N:1]1([C:7]2[N:8]=[C:9]3[NH:17][C@H:16]([C:18]([F:21])([F:20])[F:19])[CH2:15][CH2:14][N:10]3[C:11](=[O:13])[CH:12]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.[OH-].[Na+].Br[CH2:25][CH2:26][C:27]1[CH:32]=[CH:31][CH:30]=[C:29]([Cl:33])[CH:28]=1>C1(C)C=CC=CC=1.O.S([O-])(O)(=O)=O.C([N+](CCCC)(CCCC)CCCC)CCC.C(OCC)(=O)C>[Cl:33][C:29]1[CH:28]=[C:27]([CH2:26][CH2:25][N:17]2[C:9]3=[N:8][C:7]([N:1]4[CH2:6][CH2:5][O:4][CH2:3][CH2:2]4)=[CH:12][C:11](=[O:13])[N:10]3[CH2:14][CH2:15][C@H:16]2[C:18]([F:20])([F:21])[F:19])[CH:32]=[CH:31][CH:30]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

8

反応物 3

HCID 14798Sodium HydroxideHCID 1401401-(2-Bromoethyl)-3-chlorobenzeneHCID 136238743(S)-8-(Morpholin-4-yl)-2-(trifluoromethyl)-1,2,3,4-tetrahydropyrimido[1,2-a]pyrimidin-6-one

生成物 1

HCID 49854610(8S)-9-[2-(3-chloro-phenyl)ethyl]-2-(morpholin-4-yl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one収率 19.2%

試薬・触媒・溶媒 4

HCID 94433
Tetrabutylammonium hydrogen sulfate
触媒
HCID 962Water溶媒
HCID 1140Toluene溶媒
HCID 8857Ethyl Acetate溶媒

実験手順

The product is prepared according to the procedure described in Example 40, using 150 mg of (8S)-2-(morpholin-4-yl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4 H-pyrimido[1,2-a]pyrimidin-4-one in 2.5 ml of toluene are added 296 mg of sodium hydroxide in 2.5 ml of water, 33 mg of tetrabutylammonium hydrogen sulphate and 216 mg of 1-(2-bromoethyl)-3-chlorobenzene. After 44 hours at 60° C. After cooling, the reaction mixture is diluted with ethyl acetate. The organic phase is separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are concentrated to dryness under reduced pressure and the residue is purified by preparative HPLC/MS (Method D). 42 mg of (8S)-9-[2-(3-chloro-phenyl)ethyl]-2-(morpholin-4-yl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4 H-pyrimido[1,2-a]pyrimidin-4-one are thus obtained, the characteristics of which are the following:

後処理

  1. customThe product is prepared
  2. temperatureAfter cooling
  3. customThe organic phase is separated
  4. extractionthe aqueous phase is extracted with ethyl acetate
  5. concentrationThe combined organic phases are concentrated to dryness under reduced pressure
  6. customthe residue is purified by preparative HPLC/MS (Method D)

出典と根拠

ORDレコード
ord-324f1ced10c6442d886e75302abf13e7
出典データセット
uspto-grants-2014_09
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08846670B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート